Tag: IL17

Business

Akeso’s Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA by Investing.com

Hong Kong, January 26, 2025 /prnewswire/- Akeso, Inc. (9926.hk)("AkesoThe Company (or the…

Vantage Feed January 27, 2025

Importent Links

About Us
Privacy Policy
Terms of Use
Contact
Disclaimer

About US

We are a dedicated team of journalists, writers, and editors who are passionate about delivering high-quality content that informs, educates, and inspires our readers.

Quick Links

Home
My Bookmarks
About Us
Contact

Subscribe US

Subscribe my Newsletter for new posts, tips & new Articles. Let's stay updated!

Leave this field empty if you're human:

Welcome Back!

Sign in to your account

Username or Email Address

Password

Remember Me

Lost your password?

Akeso’s Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA by Investing.com

Importent Links

About US

Quick Links

Categories & Tags

Subscribe US